Physician profile
Terence Herman
NPI 1124097498
$1,857.14
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.36 · 2020: $4.68 · 2021: $55.62 · 2022: $254 · 2023: $1,498 · 2024: $16.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.11 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $290.84 | 2021-2023 | |
| Seagen INC. | $172.83 | 2023 | Tivdak, Adcetris, Tukysa |
| Celgene Corporation | $140.59 | 2022-2023 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $137.41 | 2023-2024 | Injectafer, Enhertu |
| Sobi, INC | $124.81 | 2022-2023 | |
| Lilly USA, LLC | $119.04 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $91.08 | 2023 | |
| Eisai INC. | $87.37 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.05 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $56.70 | 2022-2023 | Opdualag |
| Gilead Sciences, INC. | $54.71 | 2023 | Trodelvy |
| Astellas Pharma US INC | $50.84 | 2023 | Padcev, Xtandi |
| Genentech USA, INC. | $49.50 | 2023 | Tecentriq |
| Jazz Pharmaceuticals INC. | $43.54 | 2022-2023 | |
| Janssen Biotech, INC. | $38.21 | 2022-2023 | Darzalex |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.94 | 2023 | |
| Emd Serono, INC. | $31.24 | 2023 | Bavencio |
| Tolmar, INC. | $31.02 | 2023 | |
| Brainlab, INC. | $24.58 | 2021 | |
| Glaxosmithkline, LLC. | $22.07 | 2023 | Ojjaara |
| Pharmacosmos Therapeutics INC. | $18.33 | 2023 | Monoferric |
| Pharmaessentia USA Corporation | $18.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.16 | 2023 | Lynparza |
| Novocure INC. | $18.15 | 2022 | |
| Array Biopharma INC | $17.47 | 2023 | Lorbrena, Mektovi, Braftovi |
| Gt Medical Technologies, INC | $17.20 | 2019 | |
| Pharming Healthcare, INC. | $17.19 | 2023 | Ruconest |
| Immunogen, INC. | $17.15 | 2023 | Elahere |
| Mevion_medical_systems_inc | $15.84 | 2019-2020 | |
| Amgen INC. | $13.89 | 2022 | |
| Aveo Pharmaceuticals, INC. | $13.30 | 2023 | Fotivda |
| Karyopharm Therapeutics INC. | $12.78 | 2023 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terence Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.